Kelun Group
Kelun Group, officially known as Kelun Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in China (CN). Established in 2004, the company has rapidly expanded its operations across major regions, including Asia, Europe, and North America, solidifying its presence in the global market.
Specialising in the development and production of high-quality injectable drugs, Kelun Group is recognised for its innovative approach and commitment to research and development. The company’s core products include a diverse range of sterile injectables and oncology medications, distinguished by their advanced formulation techniques and stringent quality control measures.
With a strong market position, Kelun Group has achieved significant milestones, including numerous certifications and partnerships that enhance its reputation as a trusted provider in the pharmaceutical sector. Its dedication to excellence and patient safety continues to drive its success in the competitive landscape of pharmaceutical manufacturing.
-17 vs industry average
Kelun Group’s score of 22 is lower than 28% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Kelun Group?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Kelun Group's reported carbon emissions
Kelun Group, a pharmaceutical preparation manufacturer headquartered in CN, has reported the following carbon emissions. For 2024, total Scope 1 and Scope 2 emissions were approximately 3.33 billion kg CO2e, comprising about 2.36 billion kg CO2e from Scope 1 and approximately 483.8 million kg CO2e from Scope 2. This represents a slight increase from 2023, when total Scope 1 and Scope 2 emissions were approximately 2.66 billion kg CO2e (Scope 1: about 2.19 billion kg CO2e, Scope 2: approximately 468.9 million kg CO2e). In 2022, Kelun Group disclosed Scope 1 emissions of approximately 12.6 million kg CO2e from its processes and Scope 3 emissions of about 472 million kg CO2e for purchased goods and services, with Scope 2 data not being available for that year.
Kelun Group's emissions data is cascaded from its corporate family. While specific reduction targets are not detailed, the company's disclosures indicate it is actively managing its environmental impact within the pharmaceutical sector. The company is a current subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., from which performance data is sourced.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Kelun Group’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Kelun Group yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
Kelun Group
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project